tiprankstipranks
Regeneron upgraded to Buy on COPD opportunity at Jefferies
The Fly

Regeneron upgraded to Buy on COPD opportunity at Jefferies

Jefferies analyst Akash Tewari upgraded Regeneron Pharmaceuticals to Buy from Hold with a price target of $925, up from $675. Dupixent "well exceeded" the buy-side bar, showing a 30% reduction over placebo in patients with uncontrolled chronic obstructive pulmonary disease, the analyst tells investors in a research note. The firm thinks COPD could be a $4B opportunity for Dupixent and also increased Regeneron’s IL-33 sales potential to $2Bn given the signal in non-smokers. Despite the macro environment, Regeneron "hit two home runs within a short period of time" with Eylea data and Dupixent in COPD, contends Jefferies.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on REGN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles